Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jan 5:17:1-8.
doi: 10.2147/CEG.S348507. eCollection 2024.

Obstacles to Early Diagnosis of Acute Hepatic Porphyria: Current Perspectives on Improving Early Diagnosis and Clinical Management

Affiliations
Review

Obstacles to Early Diagnosis of Acute Hepatic Porphyria: Current Perspectives on Improving Early Diagnosis and Clinical Management

Manish Thapar et al. Clin Exp Gastroenterol. .

Abstract

Porphyrias are, for the most part, inherited disorders of the heme biosynthetic pathway which lead to accumulation of specific intermediates responsible for most of the symptoms and signs of biochemically active disease. Acute hepatic porphyrias usually come to clinical attention primarily in women in their reproductive years who present with episodic, severe, generalized abdominal pain. Such acute attacks may also be associated with tachycardia, systemic arterial hypertension, hyponatremia, recent history of dark reddish to brownish urine, and anxiety, delirium, and sensory or motor neuropathies. Diagnosing AHPs is often challenging, requiring a high index of suspicion and the appropriate testing showing elevated ALA and/or PBG in a random urine specimen. Obstacles to diagnosis include inappropriate testing for porphyrins only, inadequate sample handling, and ordering genetic testing as the initial diagnostic test. While some of these pitfalls in diagnosis are surmountable with current knowledge, others are in need of more research.

Keywords: ALA; PBG; acute intermittent porphyria; diagnosis; misdiagnosis; obstacle to diagnosis; porphyria; porphyrins; secondary coproporphyrinuria.

PubMed Disclaimer

Conflict of interest statement

Dr Manish Thapar is a consultant for Alnylam Pharmaceuticals, Disc Medicine, and Recordati Rare Diseases, outside the submitted work. Dr Herbert Bonkovsky reports grants/personal fees from Alnylam Pharma, Disc Medicine, Mitsubishi-Tanabe, NA, Calliditas, SA, Gilead Sciences, and Recordati Rare Chemicals, outside the submitted work. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
The pathway of heme synthesis, showing pathway intermediates and end-product regulation by heme. The eight steps of heme synthesis (left columns) are shown with the enzyme (middle column) that catalyzes each step. The enzymes in bold face are the clinically most prevalent porphyrias. Acute intermittent porphyria is the most common acute hepatic porphyria.

References

    1. Bonkovsky HL, Guo JT, Hou W, Li T, Narang T, Thapar M. Porphyrin and heme metabolism and the porphyrias. Compr Physiol. 2013;3(1):365–401. PMID: 23720291. doi:10.1002/cphy.c120006 - DOI - PubMed
    1. Bonkovsky HL, Maddukuri VC, Yazici C, et al. Acute porphyrias in the USA: features of 108 subjects from porphyrias consortium. Am J Med. 2014;127(12):1233–1241. doi:10.1016/j.amjmed.2014.06.036 - DOI - PMC - PubMed
    1. Bissell DM, Anderson KE, Bonkovsky HL Porphyria. N Engl J Med. 2017;377(9):862–872. - PubMed
    1. Chen B, Solis-Villa C, Hakenberg J, et al. Acute intermittent porphyria: predicted pathogenicity of HMBS variants indicates extremely low penetrance of the autosomal dominant disease. Hum Mutat. 2016;37:1215–1222. doi:10.1002/humu.23067 - DOI - PMC - PubMed
    1. Kazamel M, Pischik E, Desnick RJ. Pain in acute hepatic porphyrias: updates on pathophysiology and management. Front Neurol. 2022;13:1004125. doi:10.3389/fneur.2022.1004125 - DOI - PMC - PubMed